Rain Enhancement Technologies Holdco Inc (RAIN)

$5.80 -1.50 (-20.55%)
Market Cap 44.02M
Revenue (ttm) 0.00
Net Income (ttm) -75.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 19,569
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 36.38M
Stochastic %K N/A
Beta 0.27
Analysts N/A
Price Target N/A

Latest News on RAIN

Rain Enhancement Technologies Holdco, Inc. Announces Management Updates and Appointment of Randy Seidl as Chief Executive Officer

Feb 3, 2025, 8:00 AM EST - 2 months ago

Rain Enhancement Technologies Holdco, Inc. Announces Management Updates and Appointment of Randy Seidl as Chief Executive Officer

Pathos AI Completes Acquisition of Rain Oncology

Jan 26, 2024, 8:49 AM EST - 1 year ago

Pathos AI Completes Acquisition of Rain Oncology

RAIN ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rain Oncology Inc. - RAIN

Jan 4, 2024, 9:08 PM EST - 1 year ago

RAIN ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Rain Oncology Inc. - RAIN

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

Dec 13, 2023, 6:05 PM EST - 1 year ago

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 9, 2023, 4:01 PM EST - 1 year ago

Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update

Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

Oct 16, 2023, 8:00 AM EDT - 1 year ago

Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

Rain Oncology Inc. (RAIN) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 6:39 PM EDT - 1 year ago

Rain Oncology Inc. (RAIN) Q2 2023 Earnings Call Transcript

Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 4:05 PM EDT - 1 year ago

Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023

Jul 26, 2023, 8:00 AM EDT - 1 year ago

Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rain Oncology Inc. (RAIN) on Behalf of Investors

Jul 19, 2023, 4:00 PM EDT - 1 year ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rain Oncology Inc. (RAIN) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Rain Oncology Inc. (RAIN) on Behalf of Investors

Jul 18, 2023, 7:55 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of Rain Oncology Inc. (RAIN) on Behalf of Investors

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Rain Oncology Inc. with Losses of $100,000 to Contact the Firm

Jul 18, 2023, 6:00 AM EDT - 1 year ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Rain Oncology Inc. with Losses of $100,000 to Contact the Firm

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Jul 8, 2023, 7:00 AM EDT - 1 year ago

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

RAIN NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Rain Oncology Inc.

Jun 27, 2023, 5:45 AM EDT - 1 year ago

RAIN NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Rain Oncology Inc.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses to Contact the Firm

May 31, 2023, 11:45 AM EDT - 2 years ago

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses to Contact the Firm

Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs

May 30, 2023, 8:30 AM EDT - 2 years ago

Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses to Contact the Firm

May 25, 2023, 10:30 AM EDT - 2 years ago

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses to Contact the Firm

Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma

May 22, 2023, 8:00 AM EDT - 2 years ago

Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma

Rain Oncology, Inc. (RAIN) Q1 2023 Earnings Call Transcript

May 13, 2023, 3:42 AM EDT - 2 years ago

Rain Oncology, Inc. (RAIN) Q1 2023 Earnings Call Transcript

Rain Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Progress

May 11, 2023, 4:05 PM EDT - 2 years ago

Rain Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Progress

Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data

Apr 27, 2023, 2:36 AM EDT - 2 years ago

Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data

Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023

Apr 26, 2023, 2:34 PM EDT - 2 years ago

Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023

Rain Oncology Announces Oral Presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress

Mar 21, 2023, 5:50 AM EDT - 2 years ago

Rain Oncology Announces Oral Presentation at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress

Rain Oncology Inc. (RAIN) Q4 2022 Earnings Call Transcript

Mar 9, 2023, 9:04 PM EST - 2 years ago

Rain Oncology Inc. (RAIN) Q4 2022 Earnings Call Transcript

Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

Mar 9, 2023, 4:05 PM EST - 2 years ago

Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

Rain Oncology to Present At Oppenheimer 33rd Annual Healthcare Conference

Mar 7, 2023, 8:00 AM EST - 2 years ago

Rain Oncology to Present At Oppenheimer 33rd Annual Healthcare Conference

Rain Oncology to Report Fourth Quarter and Full Year 2022 Financial Results and Highlights of Recent Progress on March 9, 2023

Feb 23, 2023, 8:00 AM EST - 2 years ago

Rain Oncology to Report Fourth Quarter and Full Year 2022 Financial Results and Highlights of Recent Progress on March 9, 2023

Rain Oncology to Participate in the 2023 Citi Virtual Oncology Leadership Summit

Feb 9, 2023, 8:00 AM EST - 2 years ago

Rain Oncology to Participate in the 2023 Citi Virtual Oncology Leadership Summit

Rain Oncology: Multiple Data Catalysts In 2023 For This Precision Oncology Pioneer

Feb 8, 2023, 9:45 AM EST - 2 years ago

Rain Oncology: Multiple Data Catalysts In 2023 For This Precision Oncology Pioneer

UPDATE – Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference

Jan 31, 2023, 4:27 PM EST - 2 years ago

UPDATE – Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference

Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference

Jan 31, 2023, 8:00 AM EST - 2 years ago

Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference

Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology

Jan 23, 2023, 8:00 AM EST - 2 years ago

Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology